| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, Ph.D., Neurocrine's Chief Operating Officer has been appointed President and Chief Executive Officer and a member of the Board of Directors of Neurocrine Biosciences. Gary Lyons will step down as President and Chief Executive Officer of Neurocrine and will continue to serve as a member of the Board of Directors.
"While this was a very difficult decision for me, I believe the time is right for a change in leadership of Neurocrine. With three Phase II products, $180 million in cash and an extremely talented and experienced management team and dedicated staff, Neurocrine is well positioned to emerge as one of the leading biotechnology companies under Kevin's leadership," said Gary Lyons.
"The Board is indebted to Gary for his dedication and service over the past 14 years and we are grateful that he will continue to share his knowledge and expertise as a Board member as he transitions his responsibilities to Kevin," said Joe Mollica, Chairman of the Board. "Dr. Gorman has been an integral part of Neurocrine since its founding and has played key roles in the company's success over the years. We look forward to working with Kevin in his new leadership capacity in setting the strategy and direction of the company going forward."
Dr. Gorman, 50, was appointed Chief Operating Officer in September 2006
after having served as Executive Vice President and Chief Business Officer
of Neurocrine Biosciences. In this position Dr. Gorman was responsible for
R&D, Business Development and Commercial operations. Before joining
Neurocrine in 1993, Dr. Gorman was a principal of Avalon Medical Partners,
L.P. where he wa
'/>"/>
| SOURCE Neurocrine Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |